These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 8723151

  • 1. Assessment of coenzyme Q10 tolerability in Huntington's disease.
    Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I.
    Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10.
    Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF.
    Ann Neurol; 1997 Feb; 41(2):160-5. PubMed ID: 9029064
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Riluzole in Huntington's disease: a 3-year, randomized controlled study.
    Landwehrmeyer GB, Dubois B, de Yébenes JG, Kremer B, Gaus W, Kraus PH, Przuntek H, Dib M, Doble A, Fischer W, Ludolph AC, European Huntington's Disease Initiative Study Group.
    Ann Neurol; 2007 Sep; 62(3):262-72. PubMed ID: 17702031
    [Abstract] [Full Text] [Related]

  • 7. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
    [Abstract] [Full Text] [Related]

  • 8. Unified Huntington's disease rating scale: a follow up.
    Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA.
    Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 11. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, Shoulson I, McDermott MP.
    Mov Disord; 2008 Jul 15; 23(9):1223-7. PubMed ID: 18512767
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease.
    Kasparová S, Sumbalová Z, Bystrický P, Kucharská J, Liptaj T, Mlynárik V, Gvozdjáková A.
    Neurochem Int; 2006 Jan 15; 48(2):93-9. PubMed ID: 16290265
    [Abstract] [Full Text] [Related]

  • 14. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group.
    Arch Neurol; 2007 Jul 15; 64(7):938-44. PubMed ID: 17502459
    [Abstract] [Full Text] [Related]

  • 15. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 15; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.